Indazole-based Liver X Receptor (LXR) modulators with maintained atherosclerotic lesion reduction activity but diminished stimulation of hepatic triglyceride synthesis

Journal of Medicinal Chemistry

Volumn 51, Issue 22, 2008, Pages 7161-7168

  Wrobel, Jay ^a   Steffan, Robert ^a   Bowen, S Marc ^a   Magolda, Ronald ^a   Matelan, Edward ^a   Unwalla, Rayomand ^a   Basso, Michael ^a   Clerin, Valerie ^a   Gardell, Stephen J ^a   Nambi, Ponnal ^a   Quinet, Elaine ^a   Reminick, Jason I ^a   Vlasuk, George P ^a   Wang, Shuguang ^a   Feingold, Irene ^a   Huselton, Christine ^a   Bonn, Tomas ^b   Farnegardh, Mathias ^b   Hansson, Tomas ^b   Nilsson, Annika Goos ^b   Wilhelmsson, Anna ^b   Zamaratski, Edouard ^b   Evans, Mark J ^a   more..

^a PFIZER INC   (United States)

^b Karo Bio   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

2 (2 CHLORO 4 FLUOROBENZYL) 3 (4 CHLOROPHENYL) 7 (TRIFLUOROMETHYL) 2H INDAZOLE; 2 (2 CHLORO 4 FLUOROBENZYL) 3 (4 FLUOROPHENYL) 7 (TRIFLUOROMETHYL) 2H INDAZOLE; 2 (2 CHLOROBENZYL) 3 (4 CHLOROPHENYL) 7 (TRIFLUOROMETHYL) 2H INDAZOLE; 2 (2 CHLOROBENZYL) 3 (4 FLUOROPHENYL) 7 (TRIFLUOROMETHYL) 2H INDAZOLE; 2 (2 FLUOROBENZYL) 3 (4 FLUOROPHENYL) 7 (TRIFLUOROMETHYL) 2H INDAZOLE; 2 (2,4 DIMETHYLBENZYL) 3 (4 FLUOROPHENYL) 7 (TRIFLUOROMETHYL) 2H INDAZOLE; 2 (4 CHLORO 2 FLUOROBENZYL) 3 (4 CHLOROPHENYL) 7 TRIFLUOROMETHYL) 2H INDAZOLE; 2 (4 CHLOROBENZYL) 3 (4 FLUOROPHENYL) 7 (TRIFLUOROMETHYL) 2H INDAZOLE; 2 (4 FLUOROBENZYL) 3 (4 FLUOROPHENYL) 7 (TRIFLUOROMETHYL) 2H INDAZOLE; 2 BENZYL 3 ARYL 7 TRIFLUOROMETHYLINDAZOLE; 2 BENZYL 3 PHENYL 7 (TRIFLUOROMETHYL) 2H INDAZOLE; 3 (4 CHLOROPHENYL) 2 (2 FLUOROBENZYL) 7 (TRIFLUOROMETHYL) 2H INDAZOLE; 3 (4 CHLOROPHENYL) 7 (TIRFLUOROMETHYL) 2 [2 (TRIFLUOROMETHYL) BENZYL] 2H INDAZOLE; 3 (4 CHLOROPHENYL) 7 (TRIFLUOROMETHYL) 2 [4 (TRIFLUOROMETHYL) BENZYL] 2H INDAZOLE; 3 [3 [[2 CHLORO 3 (TRIFLUOROMETHYL)BENZYL](2 DIPHENYLETHYL)AMINO]PROPOXY]PHENYLACETIC ACID; ABC TRANSPORTER A1; ABC TRANSPORTER G1; FATTY ACID SYNTHASE; INDAZOLE DERIVATIVE; LIVER X RECEPTOR; LIVER X RECEPTOR AGONIST; LIVER X RECEPTOR ALPHA; LIVER X RECEPTOR BETA; N (2,2,2 TRIFLUOROETHYL) N [4 [2,2,2 TRIFLUORO 1 HYDROXY 1 (TRIFLUOROMETHOXY)ETHYL]PHENYL]BENZENESULFONAMIDE; TRIACYLGLYCEROL; UNCLASSIFIED DRUG; WAY 214950; WAY 252623; WAY 254011;

AORTA DISEASE; ARTERY LESION; ARTICLE; ATHEROSCLEROSIS; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG HALF LIFE; DRUG POTENCY; DUODENUM; FOAM CELL; GENE EXPRESSION; KNOCKOUT MOUSE; LIPID LIVER LEVEL; LIPID STORAGE; LIPOGENESIS; LIVER; MALE; MOUSE; NONHUMAN; REDUCTION KINETICS; STIMULATION; TRANSACTIVATION; TRIACYLGLYCEROL BLOOD LEVEL; UPREGULATION;

ANIMALS; ARTERIOSCLEROSIS; CELL DIFFERENTIATION; CELL LINE; CRICETINAE; CRYSTALLOGRAPHY, X-RAY; DNA-BINDING PROTEINS; HUMANS; HYDROGEN BONDING; INDAZOLES; LIGANDS; LIVER; MALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MODELS, ANIMAL; MODELS, MOLECULAR; MOLECULAR STRUCTURE; RECEPTORS, CYTOPLASMIC AND NUCLEAR; RECOMBINANT PROTEINS; STRUCTURE-ACTIVITY RELATIONSHIP; TRIGLYCERIDES;

EID: 56749177320     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm800799q     Document Type: Article

References (24)

1. Kalaany, N. Y.; Mangelsdorf, D. J. LXRs and FXR: The Yin and Yang of Cholesterol and Fat Metabolism. Annu. Rev. Physiol. 2006, 68, 159-191.
2. Beaven, S. W.; Tontonoz, P. Nuclear Receptors in Lipid Metabolism: Targeting the Heart of Dyslipidemia. Annu. Rev. Med. 2006, 57, 313-329.
3. Michael, L. F.; Schkeryantz, J. M.; Burris, T. The Pharmacology of LXR. Mini-Rev. Med. Chem. 2005, 5, 729-740.
4. Bruemmer, D.; Law, R. E. Liver X Receptors: Potential Novel Targets in Cardiovascular Diseases. Curr. Drug Targets: Cardiovasc. Haematol. Disord. 2005, 5, 533-540.
5. Tangirala, R. K.; Bischoff, E. D.; Joseph, S. B.; Wagner, B. L.; Walczak, R.; Laffitte, B. A.; Daige, C. D.; Thomas, D.; Heyman, R. A.; Mangelsdorf, D. J.; Wang, X.; Lusis, A. J.; Tontonoz, P.; Schulman, I. G. Identification of Macrophage Liver X Receptors as Inhibitors of Atherosclerosis. Proc. Natl. Acad. Sci. U.S.A. 2002, 99 (18), 11896-11901.
6. Joseph, S. B.; McKilligin, E.; Pei, L.; Watson, M. A.; Collins, A.; Laffitte, B. A.; Chen, M.; Noh, G.; Goodman, J.; Hagger, G. N.; Tran, J.; Tippin, T. K.; Wang, X.; Lusis, A. J.; Hsueh, W. A.; Law, R. E.; Collins, J. L.; Willson, T. M.; Tontonoz, P. Synthetic LXR Ligand Inhibits the Development of Atherosclerosis in Mice. Proc. Natl. Acad. Sci. U.S.A. 2002, 99, 7604-7609.
7. Schultz, J. R.; Tu, H.; Luk, A.; Repa, J. J.; Medina, J. C.; Li, L. P.; Schwendner, S.; Wang, S.; Thoolen, M.; Mangelsdorf, D. J.; Lustig, K. D.; Shan, B. Role of LXRs in Control of Lipogenesis. Genes Dev. 2000, 14 (22), 2831-2838.
8. Collins, J. L.; Fivush, A. M.; Watson, M. A.; Galardi, C. M.; Lewis, M. C.; Moore, L. B.; Parks, D. J.; Wilson, J. G.; Tippin, T. K.; Binz, J. G.; Plunket, K. D.; Morgan, D. G.; Beaudet, E. J.; Whitney, K. D.; Kliewer, S. A.; Willson, T. M. Identification of a Nonsteroidal Liver X Receptor Agonist through Parallel Array Synthesis of Tertiary Amines. J. Med. Chem. 2002, 45, 1963-1966.
9. Hu, B.; Collini, M.; Unwalla, R.; Miller, C.; Singhaus, R.; Quinet, E.; Savio, D.; Halpern, A.; Basso, M.; Keith, J.; Clerin, V.; Chen, L.; Resmini, C.; Liu, Q.-Y.; Feingold, I.; Huselton, C.; Azam, F.; Farnegardh, M.; Enroth, C.; Bonn, T.; Goos-Nilsson, A.; Wilhelmsson, A.; Nambi, P.; Wrobel, J. Discovery of Phenyl Acetic Acid Substituted Quinolines as Novel Liver X Receptor Agonists for the Treatment of Atherosclerosis. J. Med. Chem. 2006, 49, 6151-6154.
10. Hu, B.; Jetter, J.; Kaufman, D.; Singhaus, R.; Bernotas, R.; Unwalla, R.; Quinet, E.; Savio, D.; Halpern, A.; Basso, M.; Keith, J.; Clerin, V.; Chen, L.; Liu, Q.-Y.; Feingold, I.; Huselton, C.; Azam, F.; Goos-Nilsson, A.; Wilhelmsson, A.; Nambi, P.; Wrobel, J. Further Modifications on Phenyl Acetic Acid Based Quinolines as Liver X Receptor Modulators. Bioorg. Med. Chem. 2007, 15, 3321-3333.
11. Nambi, P.; Basso, M.; Chen, L.; Liu, Q.; Keith, J.; Clerin, V.; Quinet, E.; Savio, D.; Halpern, A.; Wrobel, J. WAY-254011 Inhibits Atherosclerotic Lesion Progression and Inflammatory Markers in the LDL Receptor Knockout Mice. Presented at the Keystone Meeting, Nuclear Receptors: Orphan Brothers (X3), Banff, Alberta, Canada, 2006.
12. Nambi, P.; Basso, M.; Chen, L.; Liu, Q.; Clerin, V.; Feldman, J.; Pitman, D.; Keith, J.; Quinet, E.; Wrobel, J. WAY-254011, a Novel LXR Modulator, Inhibits Atherosclerotic Lesion Progression in ApoE Knockout Mice. Presented at the XIV International Symposium on Atherosclerosis, Rome, Italy, 2006.
13. Quinet, E.; Savio, D.; Halpern, A.; Chen, L.; Schuster, G. U.; Gustafsson, J.; Basso, M.; Nambi, P. Liver X Receptor (LXR) - Regulation in LXR-Deficient Mice: Implications for Therapeutic Targeting. Mol. Pharmacol. 2006, 70, 1340-1349.
14. Lund, E. G.; Peterson, L. B.; Adams, A. D.; Lam, M. N.; Burton, C. A.; Chin, J.; Guo, Q.; Huang, S.; Latham, M.; Lopez, J. C.; Maenke, J. G.; Milot, D. P.; Mitnaul, L. J.; Rex-Rabe, S. E.; Rosa, R. L.; Tian, J. Y.; Wright, S. D.; Sparrow, C. P. Different Roles of Liver X Receptor α and β in Lipid Metabolism: Effects of an α-Selective and a Dual Agonist in Mice Deficient in Each Subtype. Biochem. Pharmacol. 2006, 71, 453-463.
15. Scott, J. The Liver X Receptor and Atherosclerosis. N. Engl. J. Med. 2007, 357 (21), 2195-2197.
16. Bradley, M. N.; Hong, C.; Chen, M.; Joseph, S. B.; Wilpitz, D. C.; Wang, X.; Aldons, J. L.; Collins, A.; Hseuh, W. A.; Collins, J. L.; Tangirala, R. K.; Tontonoz, P. Ligand Activation of LXRβ Reverses Atherosclerosis and Cellular Cholesterol Overload in Mice Lacking LXRα and apoE. J. Clin. Invest. 2007, 117, 2337-2346.
17. Wrobel, J.; Steffan, R. J.; Matelan, E.; Bowen, S. M.; Hu, B.; Collini, M.; Miller, C. P.; Unwalla, R. J.; Nambi, P.; Quinet, E.; Chen, L.; Halpern, A.; Liu, Q.-Y.; Savio, D.; Zamaratsky, E.; Kruger, L.; Wilhelmsson, A.; Goos Nilsson, A.; Ursu, C.; Arnelof, E.; Sandberg, J.; Enroth, C.; Farnegardh, M. Discovery of LXR Modulator WAY-252623. Presented at the 234th National Meeting of the American Chemical Society, Boston, MA, 2007.
18. Nambi, P.; Basso, M. D.; Chen, L.; Liu, Q.-Y.; Halpern, A.; Clerin, V.; Resmini, C.; Keith, J.; Feingold, I.; Steffan, R. J.; Wrobel, J.; Quinet, E. Abstract 1453: LXR-623, a Novel Liver X Receptor Modulator, Displays Neutral Lipid Effects in Cholesteryl Ester Transfer Protein-Expressing Species and Inhibits Atherosclerotic Lesion Progression in Low Density Lipoprotein Receptor Knockout Mice. Circulation 2007, 116, 299.
19. Figures were made using the program INSIGHT II, version 2005 (Accelrys, San Diego, CA).
20. Faernegardh, M.; Bonn, T.; Sun, S.; Ljunggren, J.; Ahola, H.; Wilhelmsson, A.; Gustafsson, J.-A.; Carlquist, M. The Three-Dimensional Structure of the Liver X Receptor β Reveals a Flexible Ligand-Binding Pocket That Can Accommodate Fundamentally Different Ligands. J. Biol. Chem. 2003, 278, 38821-38828.
21. Wouters, K.; Shiri-Sverdlov, R.; van Gorp, P. J.; van Bilsen, M.; Hofker, M. H. Understanding Hyperlipidemia and Atherosclerosis: Lessons from Genetically Modified ApoE and LDLr Mice. Clin. Chem. Lab. Med. 2005, 43, 470-479.
22. Groot, P. H.; Pearce, N. J.; Yates, J. W.; Stocker, C.; Sauermelch, C.; Doe, C. P.; Willette, R. N.; Olzinski, A.; Peters, T.; d'Epagnier, D.; Morasco, K. O.; Krawiec, J. A.; Webb, C. L.; Aravindhan, K.; Jucker, B.; Burgert, M.; Ma, C.; Marino, J. P.; Collins, J. L.; Macphee, C. H.; Thompson, S. K.; Jaye, M. Synthetic LXR Agonists Increase LDL in CETP Species. J. Lipid Res. 2005, 46, 2182-2191.
23. Plasma TG levels for compound 3 at 10 (mg/kg)/day were 395 ± 53 mg/dL and at 30 (mg/kg)/day were 913 ± 68 mg/dL.
24. Hu, B.; Quinet, E.; Unwalla, R.; Collini, M.; Jetter, J.; Dooley, R.; Andrake, D.; Nogle, L.; Savio, D.; Halpern, A.; Goos-Nilsson, A.; Wilhelmsson, A.; Nambi, P.; Wrobel, J. Carboxylic Acid Based Quinolines as Liver X Receptor Modulators That Have LXRβ Receptor Binding Selectivity. Bioorg. Med. Chem. Lett. 2008, 18 (1), 54-59.